NEW BRUNSWICK, US: Johnson & Johnson (JNJ) confirmed that it is engaged in preliminary discussions with Actelion Pharmaceuticals Ltd (ATLN) regarding a potential transaction.
There can be no guarantee any deal will result from these discussions.
The company does not mean to make any further comments concerning these discussions unless and until it is proper to do so, or a formal contract has been made.
Actelion is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. It is headquartered in Allschwil, Basel, Switzerland.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH).
No comments:
Post a Comment